• Global coverage
Chondrosarcomas are malignant cartilaginous neoplasms with diverse morphological features and clinical behavior. They account for about 20 percent of all primary malignant tumors of the bone and usually arise in the pelvis or long bones. Primary or conventional chondrosarcoma arises in preexisting normal bone and is distinguished from the rarer secondary tumors, which occur within a preexisting enchondroma or osteochondroma. The majority of chondrosarcomas are sporadic, but they may develop from the malignant transformation of osteochondromas and enchondromas. As with many cancers, the cause of chondrosarcoma is not clear. However, people with certain medical conditions have an increased risk for developing chondrosarcoma. People with chondrosarcoma usually do not feel sick. They may be able to feel a boney bump, and most patients ultimately will have pain, swelling, or limited movement that is caused by the tumor. A bone tumor is often first discovered on x-ray after a physical exam. It can be difficult to tell the difference between a benign bone tumor and chondrosarcoma on x-ray. Additional tests, including a bone scan, CT scan, MRI and PET scan, can provide more information about the tumor. Ultimately, biopsy of the tumor is the only way to make a definite diagnosis of chondrosarcoma. Complete surgical removal of the tumor, along with a wide margin of healthy tissue, has historically been the preferred treatment of chondrosarcoma.
"Chondrosarcoma - Pipeline Insight, 2021" report by Researcher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chondrosarcoma pipeline landscape is provided which includes the disease overview and Chondrosarcoma treatment guidelines. The assessment part of the report embraces, in depth Chondrosarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chondrosarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
• The companies and academics are working to assess challenges and seek opportunities that could influence Chondrosarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Chondrosarcoma.
Chondrosarcoma Emerging Drugs Chapters
This segment of the Chondrosarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chondrosarcoma Emerging Drugs
• INBRX-109: Inhibrx
INBRX-109 is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody designed to exploit the tumor-biased cell death induced by DR5 activation. In January 2021, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to INBRX-109 for the treatment of patients with unresectable or metastatic conventional chondrosarcoma. The drug is currently being evaluated in Phasr II stage of development.
• AG120: Agios Pharmaceuticals
Ivosidenib is a reversible inhibitor of IDH1 which is non-competitive with respect to the cofactor NADH. It binds to many different 132-substituted IDH1 mutants as well as the wild type enzyme. It is considered to be a slow-binder of the wild type enzyme and binds to mutant enzymes at lower concentrations, both of which may contribute its selectivity. Ivosidenib is a first in class isocitrate dehydrogenase-1 (IDH1) approved for use by the FDA in acute myeloid leukemia (AML) in July 2018. Ivosidenib is now available in the United States under the trade name Tibsovo marketed by Agios Pharmaceuticals, Inc. A Phase II study is being done to see whether AG-120 is an effective and safe treatment for people with advanced/metastatic or recurrent chondrosarcoma that has IDH1 mutation.
Further product details are provided in the report……..
Chondrosarcoma: Therapeutic Assessment
This segment of the report provides insights about the different Chondrosarcoma drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Chondrosarcoma
There are approx. 8+ key companies which are developing the therapies for Chondrosarcoma. The companies which have their Chondrosarcoma drug candidates in the most advanced stage, i.e. Phase II include, Inhibrx.
Researcher’s report covers around 8+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Chondrosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Chondrosarcoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chondrosarcoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chondrosarcoma drugs.
Chondrosarcoma Report Insights
• Chondrosarcoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Chondrosarcoma Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Chondrosarcoma drugs?
• How many Chondrosarcoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chondrosarcoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chondrosarcoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chondrosarcoma and their status?
• What are the key designations that have been granted to the emerging drugs?
Frequently Asked Questions
- By product type
- By End User/Applications
- By Technology
- By Region